Belguise K, Guo S, Sonenshein GE (2007) Activation of FOXO3a by the green tea polyphenol epigallocatechin-3-gallate induces estrogen receptor alpha expression reversing invasive phenotype of breast cancer cells. Cancer Res 67:5763–5770
Article CAS PubMed Google Scholar
Bimonte S, Cascella M (2020) The potential roles of epigallocatechin-3-gallate in the treatment of ovarian cancer: Current state of knowledge. Drug Des Devel Ther 14:4245
Article CAS PubMed PubMed Central Google Scholar
Cabrera C, Artacho R, Giménez R (2006) Beneficial effects of green tea—a review. J Am Coll Nutr 25:79–99
Article CAS PubMed Google Scholar
Chacko SM, Thambi PT, Kuttan R, Nishigaki I (2010) Beneficial effects of green tea: a literature review. Chin Med 5:1–9
Chandra A, Pius C, Nabeel M, Nair M, Vishwanatha JK, Ahmad S, Basha R (2019) Ovarian cancer: Current status and strategies for improving therapeutic outcomes. Cancer Med 8:7018–7031
Article PubMed PubMed Central Google Scholar
Cortez AJ, Tudrej P, Kujawa KA, Lisowska KM (2018) Advances in ovarian cancer therapy. Cancer Chemother Pharmacol 81:17–38
Article CAS PubMed Google Scholar
Cui CJ, Jin JL, Guo LN, Sun J, Wu NQ, Guo YL, Liu G, Dong Q, Li JJ (2020) Beneficial impact of epigallocatechingallate on LDL-C through PCSK9/LDLR pathway by blocking HNF1alpha and activating FoxO3a. J Transl Med 18:195
Article CAS PubMed PubMed Central Google Scholar
Du Bois A, Lück H-J, Meier W, Adams H-P, Möbus V, Costa S, Bauknecht T, Richter B, Warm M, Schröder W (2003) A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95:1320–1329
Du BX, Lin P, Lin J (2022) EGCG and ECG induce apoptosis and decrease autophagy via the AMPK/mTOR and PI3K/AKT/mTOR pathway in human melanoma cells. Chin J Nat Med 20:290–300
Eliopoulos AG, Kerr DJ, Herod J, Hodgkins L, Krajewski S, Reed JC, Young LS (1995) The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. Oncogene 11:1217–1228
Eng QY, Thanikachalam PV, Ramamurthy S (2018) Molecular understanding of Epigallocatechin gallate (EGCG) in cardiovascular and metabolic diseases. J Ethnopharmacol 210:296–310
Article CAS PubMed Google Scholar
Fei M, Zhao Y, Wang Y, Lu M, Cheng C, Huang X, Zhang D, Lu J, He S, Shen A (2009) Low expression of Foxo3a is associated with poor prognosis in ovarian cancer patients. Cancer Invest 27:52–59
Article CAS PubMed Google Scholar
Gan R-Y, Li H-B, Sui Z-Q, Corke H (2018) Absorption, metabolism, anti-cancer effect and molecular targets of epigallocatechin gallate (EGCG): An updated review. Crit Rev Food Sci Nutr 58:924–941
Article CAS PubMed Google Scholar
Huh SW, Bae SM, Kim Y-W, Lee JM, Namkoong SE, Lee IP, Kim SH, Kim CK, Ahn WS (2004) Anticancer effects of (−)-epigallocatechin-3-gallate on ovarian carcinoma cell lines. Gynecol Oncol 94:760–768
Article CAS PubMed Google Scholar
Jankun J, Selman SH, Swiercz R, Skrzypczak-Jankun E (1997) Why drinking green tea could prevent cancer. Nature 387:561–561
Article CAS PubMed Google Scholar
Jayson GC, Kohn EC, Kitchener HC, Ledermann JA (2014) Ovarian cancer. The Lancet 384:1376–1388
Katoh M, Katoh M (2004) Human FOX gene family (Review). Int J Oncol 25:1495–1500
Levanon K, Sapoznik S, Bahar-Shany K, Brand H, Shapira-Frommer R, Korach J, Hirsch MS, Roh MH, Miron A, Liu JF (2014) FOXO3a loss is a frequent early event in high-grade pelvic serous carcinogenesis. Oncogene 33:4424–4432
Article CAS PubMed Google Scholar
Liu Y, Ao X, Ding W, Ponnusamy M, Wu W, Hao X, Yu W, Wang Y, Li P, Wang J (2018) Critical role of FOXO3a in carcinogenesis. Mol Cancer 17:1–12
Luo KW, Lung WY, Chun X, Luo XL, Huang WR (2018) EGCG inhibited bladder cancer T24 and 5637 cell proliferation and migration via PI3K/AKT pathway. Oncotarget 9:12261–12272
Article PubMed PubMed Central Google Scholar
Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J, Karlan BY (2016) Ovarian cancer. Nat Rev Dis Prim 2:1–22
Nagle DG, Ferreira D, Zhou Y-D (2006) Epigallocatechin-3-gallate (EGCG): chemical and biomedical perspectives. Phytochemistry 67:1849–1855
Article CAS PubMed PubMed Central Google Scholar
Nakamura N, Ramaswamy S, Vazquez F, Signoretti S, Loda M, Sellers WR (2000) Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN. Mol Cell Biol 20:8969–8982
Article CAS PubMed PubMed Central Google Scholar
Niu Y, Na L, Feng R, Gong L, Zhao Y, Li Q, Li Y, Sun C (2013) The phytochemical, EGCG, extends lifespan by reducing liver and kidney function damage and improving age-associated inflammation and oxidative stress in healthy rats. Aging Cell 12:1041–1049
Article CAS PubMed Google Scholar
Pokhriyal R, Hariprasad R, Kumar L, Hariprasad G (2019) Chemotherapy resistance in advanced ovarian cancer patients. Biomark Cancer 11:1179299X19860815
Article PubMed PubMed Central Google Scholar
Porter AG, Jänicke RU (1999) Emerging roles of caspase-3 in apoptosis. Cell Death Differ 6:99–104
Article CAS PubMed Google Scholar
Rao SD, Pagidas K (2010) Epigallocatechin-3-gallate, a natural polyphenol, inhibits cell proliferation and induces apoptosis in human ovarian cancer cells. Anticancer Res 30:2519–2523
Reiterer M, Milton SL (2020) Induction of foxo3a protects turtle neurons against oxidative stress. Comp Biochem Physiol A Mol Integr Physiol 243:110671
Article CAS PubMed PubMed Central Google Scholar
Sandercock J, Parmar M, Torri V, Qian W (2002) First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence. Br J Cancer 87:815–824
Article CAS PubMed PubMed Central Google Scholar
Sen G, Sarkar N, Nath M, Maity S (2020) Bioactive components of tea. Arch Food Nutr Sci 4:001–009
Shankar S, Chen Q, Srivastava RK (2008) Inhibition of PI3K/AKT and MEK/ERK pathways act synergistically to enhance antiangiogenic effects of EGCG through activation of FOXO transcription factor. J Mol Signal 3:7
Article PubMed PubMed Central Google Scholar
Singh BN, Shankar S, Srivastava RK (2011) Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications. Biochem Pharmacol 82:1807–1821
Article CAS PubMed PubMed Central Google Scholar
Stewart C, Ralyea C, Lockwood S (2019) Ovarian cancer: an integrated review. Semin Oncol Nurs 32:151–156
Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, Gaudet MM, Jemal A, Siegel RL (2018) Ovarian cancer statistics, 2018. CA Cancer J Clin 68:284–296
Article PubMed PubMed Central Google Scholar
Trudel D, Labbé DP, Araya-Farias M, Doyen A, Bazinet L, Duchesne T, Plante M, Grégoire J, Renaud M-C, Bachvarov D (2013) A two-stage, single-arm, phase II study of EGCG-enriched green tea drink as a maintenance therapy in women with advanced stage ovarian cancer. Gynecol Oncol 131:357–361
Wang F, Chang Z, Fan Q, Wang L (2014) Epigallocatechin-3-gallate inhibits the proliferation and migration of human ovarian carcinoma cells by modulating p38 kinase and matrix metalloproteinase-2. Mol Med Report 9:1085–1089
Wang X, Jiang P, Wang P, Yang CS, Wang X, Feng Q (2015) EGCG enhances cisplatin sensitivity by regulating expression of the copper and cisplatin influx transporter CTR1 in ovary cancer. Plos One 10:e0125402
Article PubMed PubMed Central Google Scholar
Wang Z-Q, Stingl L, Morrison C, Jantsch M, Los M, Schulze-Osthoff K, Wagner EF (1997) PARP is important for genomic stability but dispensable in apoptosis. Genes Dev 11:2347–2358
Article CAS PubMed PubMed Central Google Scholar
Wolfram S (2007) Effects of green tea and EGCG on cardiovascular and metabolic health. J Am Coll Nutr 26:373S-388S
Comments (0)